Novartis' Phase 3 pelacarsen trial fails primary endpoint; setback for RPRX royalties
Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population, Royalty Pharma said Friday. The result removes a major potential royalty-growth catalyst for RPRX, although the filing’s full financial impact and any subgroup findings remain to be established.
The story
Royalty Pharma said Sept. 4 that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary endpoint. The study tested whether the antisense oligonucleotide could reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), or Lp(a). The endpoint combined cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularization requiring hospitalization.
The result is a setback for a program aimed at a genetically defined cardiovascular-risk population. HORIZON was designed to test the clinical-outcomes benefit of lowering Lp(a), rather than merely demonstrating a change in the biomarker. The principal corporate link is between Novartis, the developer of pelacarsen, and Royalty Pharma, which has an economic interest in approved or commercialized medicines through royalty arrangements. A failed primary endpoint can reduce the probability that a program reaches commercialization or generates the expected royalty stream. RPRX's fiscal-2025 revenue of $2.4B, up 5.1% year over year, with diluted EPS of $1.78 and a 32.4% net margin reflects the company's overall performance.
The topline announcement is not a complete readout of the trial. Key questions remain about whether a subgroup met the endpoint, how safety findings affect the risk profile, and whether Novartis plans additional analysis or development.
The next useful disclosures are the full HORIZON data, including the hazard ratio, confidence interval, statistical significance, subgroup results and safety profile. Investors will also need Novartis' stated development decision and Royalty Pharma's next filing or earnings commentary to determine how the result affects expected cash flows.
Our read · Fri, Sep 4
Royalty Pharma (RPRX) said Novartis’ Phase 3 HORIZON trial for pelacarsen failed to reduce cardiovascular events in the overall study population.
Why. The immediate issue is cash-flow optionality: a failed primary endpoint lowers the probability that pelacarsen becomes a meaningful royalty asset, while RPRX’s supplied figures do not identify how much of its $2.4B revenue base depends on the program. The read is negative, but the missing treatment-effect, subgroup and accounting details prevent a quantified single-name call until Novartis and Royalty Pharma provide a fuller update.
Both cases
What could change this view: The trade read is weakened if the full HORIZON dataset shows a clinically meaningful prespecified subgroup, or if Royalty Pharma discloses that pelacarsen has little effect on expected royalty cash flows.
Who reported it · 1
Keep reading
Latest on the Wire
Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsContinue on the Wire →Latest on the Wire
Poland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire as Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →